Harvard Bioscience, Inc. · NASDAQ:HBIO

Harvard Bioscience — Q3 2026 Earnings Presentation

15 slides from Harvard Bioscience's earnings presentation, Nov 10, 2026

  1. Slide 1: 3Q26 Earnings Presentation

    NASDAQ: HBIO 3Q26 Earnings Presentation John Duke, President & CEO Mark Frost, CFO & Treasurer November 10, 2026

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified

  3. Slide 3: Third Quarter Operating & Financial Summary

    Third Quarter Operating & Financial Summary  3Q26 results:  Revenue of $22.2 million, up 8% year-over-year driven by strong sales to CROs and customers in China; marking second consecutive quarter of strong year-over-year revenue growth  Adjusted gross margin of 57.1%, including higher volume in

  4. Slide 4: 3Q26 Highlights

    3Q26 Highlights Income Statement Components ($ in millions except %) 3Q26 3Q25 Revenue 22.2 20.6 Gross Margin 12.3 12.0 % of Revenue 55.4% 58.4% Operating Expenses 13.5 11.8 % of Revenue 60.6% 57.4% Operating Income (Loss) (1.2) 0.2 % of Revenue (5.2)% 1.0% Adjusted Operating Income* 1.2 1.5 % of Re

  5. Slide 5: 3Q26 Revenue Breakdown

    3Q26 Revenue Breakdown HBIO Revenue 3Q26 3Q25 % Var Americas $11.3M $10.4M 9% Americas increase driven by CRO and distributor growth EMEA $6.3M $6.6M (5%) EMEA decrease driven by softer demand in Academic and Pharma APAC $4.6M $3.5M 29% APAC increase primarily driven by Respiratory, Telemetry, and F

  6. Slide 6: 3Q26 Earnings, Cash & Debt

    3Q26 Earnings, Cash & Debt $ Million except per share data EARNINGS (LOSS) PER SHARE* YTD CASH FLOW FROM OPERATIONS NET DEBT* $(0.04) $(0.06) $(0.28) $6.8 $35.1 $27.5 $(0.6) $(0.58) 3Q25 3Q26 3Q25 3Q26 YTD25 YTD26 As of 3Q25 As of 3Q26 GAAP ADJUSTED * Non-GAAP measure, see Slides 10-14 for reconcili

  7. Slide 7: Outlook

    Outlook 7

  8. Slide 8: Outlook

    Outlook REVENUE ADJ. GROSS MARGIN ADJ. EBITDA 4Q26 Revenue between $23.7M - $25.5M 4Q26 GM between 59% - 61% 4Q26 Adj. EBITDA between $3.8M - $4.2M FY26 Revenue growth between 3% - 5% FY26 GM between 57% - 59% FY26 Adj. EBITDA between (1%) - 4% growth (Lowered from 6% - 10%) 8

  9. Slide 9: Appendix

    Appendix 9

  10. Slide 10: Non-GAAP Reconciliation Table – Currency

    Non-GAAP Reconciliation Table – Currency Three Months Ended September 30, Nine Months Ended September 30, Non-GAAP revenue on a constant currency basis 2026 2025 Growth Rates 2026 2025 Growth Rates Total revenues $ 22,196 $ 20,591 7.8% 65,678 62,815 4.6% Effects of foreign currency rate fluctuations

  11. Slide 11: Non-GAAP Reconciliation Table – Gross Margin

    Non-GAAP Reconciliation Table – Gross Margin Three Months Ended September 30, Nine Months Ended September 30, Non-GAAP Gross Profit and Non-GAAP Gross Margin 2026 2025 2026 2025 Amount Margin Amount Margin Amount Margin Amount Margin (in thousands) Gross profit $ 12,307 55.4% $ 12,021 58.4% $ 37,181

  12. Slide 12: Non-GAAP Reconciliation Table – Adjusted Operating Income

    Non-GAAP Reconciliation Table – Adjusted Operating Income Three Months Ended Nine Months Ended September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 GAAP operating (loss) income $ (1,150) $ 197 $ (3,302) $ (50,290) Stock-based compensation 436 324 1,073 1,396 Acquired asset amo

  13. Slide 13: Non-GAAP Reconciliation Table – Adjusted EBITDA

    Non-GAAP Reconciliation Table – Adjusted EBITDA Three Months Ended Nine Months Ended September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 GAAP net loss $ (2,623) $ (1,231) $ (8,957) $ (53,853) Stock-based compensation 436 324 1,073 1,396 Acquired asset amortization 365 855 2,0

  14. Slide 14: Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt

    Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt Three Months Ended Nine Months Ended September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 Diluted loss per share (GAAP) * $ (0.58) $ (0.28) $ (1.99) $ (12.15) Diluted adjusted loss per share * $ (0.06) $ (0.04) $ (0.53)

  15. Slide 15: 15

    15

Harvard Bioscience — Q3 2026 Earnings Presentation on 6ix